glutathione cancer cells

glutathione cancer cells A Activatable Ion Channel Induces Apoptosis in by Depleting Intracellular Glutathione Levels - Malla - 2020 - Angewandte Chemie International Edition Frontiers | Glutathione Peroxidase 4

Name: glutathione cancer cells A Activatable Ion Channel Induces Apoptosis in by Depleting Intracellular Glutathione Levels - Malla - 2020 - Angewandte Chemie International Edition Frontiers | Glutathione Peroxidase 4
Brand: ldesquadrias.com.br
SKU: 89229076590
Price: 21.58 USD
Availability: InStock
Rating: 4.5922 (22 reviews)

Frontiers Glutathione Peroxidase 4 as a Therapeutic Target for Anti Colorectal Cancer Drug Tolerant Persister Cells A glutathione activated anthraquinone based photosensitizer for selective photodynamic therapy of cancer cells overexpressing glutathione ScienceDirect glutathione cancer cell Depletion and Stalwart Anticancer Activity of Metallotherapeutics Inducing Programmed Death: Opening a New Window for Therapy Human cancer associated fibroblasts enhance glutathione Glutathione in Cancer Cell Death Glutathione & Cancer Role of Glutathione in Cancer Prevention Glyteine Glutathione Dependent Pathways in Cancer Cells

SKU: 89229076590 · From ldesquadrias.com.br

4.6

USD21.58 USD65.58

Pay in 4 interest-free payments of $5.39 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Jul 31 - Aug 5

Description

Through a series of structure-activity relationship (SAR) studies, the authors optimized the peptide sequence and introduced a C20 fatty diacid via a -glutamic acid linker to the N-terminus

Pagan, C

For instance, the AZA-BD@PC NP platform depletes intracellular cysteine to disrupt GSH synthesis while generating HS

Nov-Dec 1987;15(6):379-382

Duration of Effect: 6-12 months Storage: Sealed, unopened vials at room temperature (1~30C) Shelf life: 2 years from manufacturing date Manufacturer: Penmix Co., Ltd

In sensitivity analyses excluding patients using nasogastric tubes or erythropoietin, dabigatran users maintained a lower risk of the composite outcome than rivaroxaban users and a lower intracranial bleeding risk than apixaban and edoxaban users